|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 October 2001, Vol. 98, No. 7, pp. 2269-2271
BRIEF REPORT
Serum osteoprotegerin levels are reduced in patients with
multiple myeloma with lytic bone disease
Carina Seidel,
Øyvind Hjertner,
Niels Abildgaard,
Lene Heickendorff,
Martin Hjorth,
Jan Westin,
Johan Lanng Nielsen,
Henrik Hjorth-Hansen,
Anders Waage,
Anders Sundan, and
Magne Børset for The Nordic Myeloma Study Group
From the Institute of Cancer Research and Molecular
Biology, and the Section of Hematology, Department of Internal
Medicine, University Hospital, Norwegian University of Science and
Technology, Trondheim, Norway; the Department of Hematology, Lund
University Hospital, Lund, Sweden; the Department of Medicine,
Lidköping Hospital, Lidköping, Sweden; and the Department
of Hematology and Department of Clinical Biochemistry, Aarhus
University Hospital, Aarhus, Denmark.
Osteoprotegerin (OPG), the neutralizing decoy receptor for the
osteoclast activator RANK ligand, was measured in serum taken from
patients with multiple myeloma at the time of diagnosis. Median OPG was
lower in the patients with myeloma (7.4 ng/mL; range, 2.6-80;
n = 225) than in healthy age- and sex-matched controls (9.0 ng/mL;
range 5.1-130; n = 40; P = .02). Importantly, OPG levels were associated with degree of radiographically assessed skeletal destruction (P = .01). The median OPG level in
patients lacking osteolytic lesions was 9.1 ng/mL, as compared with 7.6 ng/mL and 7.0 ng/mL, respectively, in patients with minor or advanced osteolytic disease. Furthermore, OPG levels were associated with World
Health Organization performance status (P = .003) and
correlated to serum levels of carboxy-terminal propeptide of type I
procollagen (PICP; P < .001) but not with clinical stage
or survival. These findings suggest impaired OPG function in myeloma
and give a rationale for OPG as a therapeutic agent against myeloma
bone disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Silvestris, S. Ciavarella, M. De Matteo, M. Tucci, and F. Dammacco
Bone-Resorbing Cells in Multiple Myeloma: Osteoclasts, Myeloma Cell Polykaryons, or Both?
Oncologist,
March 1, 2009;
14(3):
264 - 275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-W. Qiang, Y. Chen, O. Stephens, N. Brown, B. Chen, J. Epstein, B. Barlogie, and J. D. Shaughnessy Jr
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
Blood,
July 1, 2008;
112(1):
196 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Vega, N. M. Maalouf, and K. Sakhaee
The Role of Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications
J. Clin. Endocrinol. Metab.,
December 1, 2007;
92(12):
4514 - 4521.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Benoliel, J. Epstein, E. Eliav, R. Jurevic, and S. Elad
Orofacial Pain in Cancer: Part I--Mechanisms
Journal of Dental Research,
June 1, 2007;
86(6):
491 - 505.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Heath, K. Vanderkerken, X. Cheng, O. Gallagher, M. Prideaux, R. Murali, and P. I. Croucher
An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma
Cancer Res.,
January 1, 2007;
67(1):
202 - 208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Richardson, T. Hideshima, and K. C. Anderson
Plasma cell dyscrasias
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
298 - 327.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Roodman
New potential targets for treating myeloma bone disease.
Clin. Cancer Res.,
October 15, 2006;
12(20):
6270s - 6273s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rogers and R. Eastell
Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment
J. Clin. Endocrinol. Metab.,
November 1, 2005;
90(11):
6323 - 6331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Shibata, M. Abe, K. Hiura, J. Wilde, K. Moriyama, T. Sano, K.-i. Kitazoe, T. Hashimoto, S. Ozaki, S. Wakatsuki, et al.
Malignant B-Lymphoid Cells with Bone Lesions Express Receptor Activator of Nuclear Factor-{kappa}B Ligand and Vascular Endothelial Growth Factor to Enhance Osteoclastogenesis
Clin. Cancer Res.,
September 1, 2005;
11(17):
6109 - 6115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Colucci, G. Brunetti, R. Rizzi, A. Zonno, G. Mori, G. Colaianni, D. Del Prete, R. Faccio, A. Liso, S. Capalbo, et al.
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction
Blood,
December 1, 2004;
104(12):
3722 - 3730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Hofbauer and M. Schoppet
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
JAMA,
July 28, 2004;
292(4):
490 - 495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Urch
The pathophysiology of cancer-induced bone pain: current understanding
Palliative Medicine,
June 1, 2004;
18(4):
267 - 274.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G Livshits, I Pantsulaia, S Trofimov, and E Kobyliansky
Genetic influences on the circulating cytokines involved in osteoclastogenesis
J. Med. Genet.,
June 1, 2004;
41(6):
e76 - e76.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley
Treatment of multiple myeloma
Blood,
January 1, 2004;
103(1):
20 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Younes and M. E. Kadin
Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
J. Clin. Oncol.,
September 15, 2003;
21(18):
3526 - 3534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Terpos, R. Szydlo, J. F. Apperley, E. Hatjiharissi, M. Politou, J. Meletis, N. Viniou, X. Yataganas, J. M. Goldman, and A. Rahemtulla
Soluble receptor activator of nuclear factor {kappa}B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index
Blood,
August 1, 2003;
102(3):
1064 - 1069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dovio, M. L. Sartori, and A. Angeli
Correspondence re: A. Lipton et al., Serum Osteoprotegerin Levels in Healthy Controls and Cancer Patients. Clin. Cancer Res., 8: 2306-2310, 2002.
Clin. Cancer Res.,
June 1, 2003;
9(6):
2384 - 2385.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Sezer, U. Heider, I. Zavrski, C. A. Kuhne, and L. C. Hofbauer
RANK ligand and osteoprotegerin in myeloma bone disease
Blood,
March 15, 2003;
101(6):
2094 - 2098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Shipman and P. I. Croucher
Osteoprotegerin Is a Soluble Decoy Receptor for Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo2 Ligand and Can Function as a Paracrine Survival Factor for Human Myeloma Cells
Cancer Res.,
March 1, 2003;
63(5):
912 - 916.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot
Advances in Biology and Therapy of Multiple Myeloma
Hematology,
January 1, 2003;
2003(1):
248 - 278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Standal, C. Seidel, O. Hjertner, T. Plesner, R. D. Sanderson, A. Waage, M. Borset, and A. Sundan
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells
Blood,
September 26, 2002;
100(8):
3002 - 3007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman
Multiple Myeloma
Hematology,
January 1, 2002;
2002(1):
214 - 240.
[Abstract]
[Full Text]
|
|
|
|
|
